Log in

ASX:KZAKazia Therapeutics Stock Price, Forecast & News

Add
Compare
Today's Range N/A
50-Day Range
A$0.40
MA: A$0.40
A$0.40
52-Week Range N/A
Volume47,736 shs
Average VolumeN/A
Market Capitalization$28.87 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops therapies for a range of oncology indications. Its lead product is GDC-0084, a small molecule inhibitor of the PI3K / AKT / mTOR pathway that is in Phase II clinical trials to treat glioblastoma multiforme. The company is also developing TRX-E-002-1 (Cantrixil), a third-generation benzopyran molecule, which is in Phase I clinical trials to treat ovarian cancer. It has collaboration agreements with The University of York, The Children's Cancer Institute Australia, The Mater Institute in Queensland, the University of Boston, and St Jude Children's Research Hospital, as well as Dana-Farber Cancer Institute. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was founded in 1994 and is based in Sydney, Australia.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 3.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.08 out of 5 stars


Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone61 2 9472 4101

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$1.40 million
Book ValueA$0.17 per share

Profitability

Miscellaneous

EmployeesN/A
Market Cap$28.87 million
Next Earnings DateN/A
OptionableNot Optionable

Receive KZA News and Ratings via Email

Sign-up to receive the latest news and ratings for KZA and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Kazia Therapeutics (ASX:KZA) Frequently Asked Questions

Has Kazia Therapeutics been receiving favorable news coverage?

News stories about KZA stock have trended somewhat negative on Thursday, according to InfoTrie Sentiment Analysis. InfoTrie identifies negative and positive media coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Kazia Therapeutics earned a media sentiment score of -1.4 on InfoTrie's scale. They also assigned headlines about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the stock's share price in the near future.
View the latest news about Kazia Therapeutics
.

Who are some of Kazia Therapeutics' key competitors?

Who are Kazia Therapeutics' key executives?

Kazia Therapeutics' management team includes the following people:
  • Dr. James Garner M.A.I.C.D., M.B.A., B.Sc., M.A., MBA, MBBS, B.Sc (, CEO, MD & Exec. Director (Age 46)
  • Ms. Gabrielle Heaton, Director of Fin. & Admin.
  • Ms. Catherine Jane Hill, Company Sec. (Age 60)
  • Kym Robins, Director of Marketing & Communications
  • Dr. Justine R. Stehn B.Sc (Hons), Ph.D., Director of ATM Program

What is Kazia Therapeutics' stock symbol?

Kazia Therapeutics trades on the ASX under the ticker symbol "KZA."

How big of a company is Kazia Therapeutics?

Kazia Therapeutics has a market capitalization of $0.00 and generates $1.40 million in revenue each year.

What is Kazia Therapeutics' official website?

The official website for Kazia Therapeutics is www.kaziatherapeutics.com.

How can I contact Kazia Therapeutics?

The company can be reached via phone at 61 2 9472 4101.

This page was last updated on 8/6/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.